Pioneering Medicines: Executive Director / Vice President

About Pioneering Medicines:

What if... We could harness the power of Flagship’s scientific platforms and create novel treatment options that benefit more patients, sooner?

Pioneering Medicines, an initiative of Flagship Pioneering, is building a world-class biopharmaceutical R&D capability focused on conceiving and developing life-changing treatments for patients by harnessing the power of Flagship’s scientific platforms and applying those innovative approaches to serious diseases with unmet medical need. Unique to Pioneering Medicines’ approach is the opportunity to combine platforms to create truly novel and potentially transformative treatments. 

About Flagship Pioneering:

Flagship Pioneering conceives, creates, resources, and develops first-in-category life science platform companies to transform human health and sustainability. Since its founding in 2000, the firm has originated and fostered the development of more than 100 scientific ventures, resulting in over $34 billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents.  

Position Summary:

Pioneering Medicines is seeking a highly motivated and experienced leader with deep subject matter expertise in AI/ML applied to drug development, spanning portfolio strategy, operations, preclinical and clinical activities. The successful candidate will work cross-functionally within Pioneering Medicines and across the broader Flagship ecosystem to identify, prioritize, and drive projects from ideation through implementation. This candidate will also work with a team to advance existing strategic efforts. 

Key Responsibilities: 

• Lead and drive strategic initiatives to integrate AI technologies in PM’s operations and development processes, ensuring alignment with PM and Flagship’s broader goals.
• Collaborate with the Explorations team to continuously survey and analyze the state-of-the-art in AI, identifying emerging trends, opportunities, and potential areas of disruption.
• Work closely with senior leadership and division heads, including R&D, TechOps, and Portfolio Strategy & Operations, to develop and implement a comprehensive AI strategy.
• Vigilantly oversee the execution of the AI strategy, coordinating with the Strategy & Ops team to ensure the seamless orchestration of AI capabilities into existing operational workflows.
• Establish strong working relationships with FSP teams to leverage their expertise in the rollout of AI implementations, including working with Pioneering Intelligence to identify synergies and potential collaborations.
• Regular and effective reporting to PM’s senior leadership on the progress, opportunities, challenges, and ROI of AI implementations.
• Stay up-to-date on the latest AI regulatory guidelines and industry best practices, ensuring the organization’s adherence to all necessary rules and standards.

Minimum Qualifications:

• Advanced degree in life sciences, engineering, computational science, or a related field, with significant industry experience.
• Exemplary understanding of AI/ML and its potential in the pharmaceutical landscape.
• Demonstrable ability to lead, manage, and inspire diverse teams.
• Strong communication skills, presenting complex concepts to non-experts in a clear, understandable manner.

Mindset & Traits:

• An innovative and strategic thinker, never taking things at face value.
• A proactive and continuous learner, always seeking the ’what’s next’ and asking “what if” of AI/ML in drug development.
• A team player, who sees the collaborative potential in every interaction.
• Adaptable and resilient, thriving in an entrepreneurial and dynamic environment.

Values and Behaviors 

• Entrepreneurial spirit 
• Mission oriented and dedicated to bringing breakthrough therapies to patients
• Has courage to take risks and bold action to advance novel treatments
• Motivates and encourages colleagues and team members at all levels 
• Fosters a growth oriented, high energy, and encouraging environment 
• Ability to hold oneself and others accountable for commitments in an assertive and positive manner 

More About Flagship Pioneering

We are creative optimists and we would love for you to consider joining our team!  See all our open opportunities across Flagship Pioneering’s Ecosystem!

Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability. Since its launch in 2000, the firm has applied a unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $34 billion in aggregate value. To date, Flagship is backed by more than $4.4 billion of aggregate capital commitments, of which over $1.9 billion has been deployed toward the founding and growth of its pioneering companies alongside more than $10 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including:  Axcella Health (NASDAQ: AXLA), Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO),  Foghorn Therapeutics, Indigo Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology, Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS). 

We believe pioneering is best done by teams, and that it is a process that can be taught, learned, and replicated.  Learn more about our Company Creation Model.

Can Breakthrough Innovations Be Made Systematically? A Conversation With Noubar Afeyan, Flagship Pioneering’s CEO. 

Recruitment & Staffing Agencies:  Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates.  The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team.   Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.

#LI-TD1